Reimplantation of a Fluocinolone Acetonide Sustained Drug Delivery Implant for Chronic Uveitis

American Journal of Ophthalmology

Volumn 145, Issue 4, 2008, Pages

  Jaffe, Glenn J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; CEFTAZIDIME; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; VANCOMYCIN;

ADULT; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DEMOGRAPHY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG IMPLANT; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC DISEASE; INFLAMMATION; INTRAOCULAR PRESSURE; KAPLAN MEIER METHOD; MALE; MULTIPLE SCLEROSIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; REIMPLANTATION; RETINA DETACHMENT; SARCOIDOSIS; STAPHYLOCOCCUS EPIDERMIDIS; STATISTICAL ANALYSIS; SURGICAL TECHNIQUE; UVEITIS; VISUAL ACUITY;

EID: 40849097594     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2007.11.008     Document Type: Article

References (13)

1. Suttorp-Schulten M.S., and Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 80 (1996) 844-848
2. Rothova A., Suttorp-van Schulten M.S., Frits Treffers W., and Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80 (1996) 332-336
3. Durrani O.M., Tehrani N.N., Marr J.E., Moradi P., Stavrou P., and Murray P.I. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 88 (2004) 1159-1162
4. Jabs D.A., Rosenbaum J.T., Foster C.S., et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130 (2000) 492-513
5. Jabs D.A., and Akpek E.K. Immunosuppression for posterior uveitis. Retina 25 (2005) 1-18
6. Jabs D.A. Treatment of ocular inflammation. Ocul Immunol Inflamm 12 (2004) 163-168
7. Kok H., Lau C., Maycock N., McCluskey P., and Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 112 (2005) 1916.e1-1916.e7
8. Helm C.J., and Holland G.N. The effects of posterior sub-Tenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol 120 (1995) 55-64
9. Jaffe G.J., McCallum R.M., Branchaud B., Skalak C., Butuner Z., and Ashton P. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 112 (2005) 1192-1198
10. Jaffe G.J., Martin D., Callanan D., Pearson P.A., Levy B., and Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 113 (2006) 1020-1027
11. Jaffe G.J., Yang C.H., Guo H., Denny J.P., Lima C., and Ashton P. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 41 (2000) 3569-3575
12. Jaffe G.J., Ben-Nun J., Guo H., Dunn J.P., and Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 107 (2000) 2024-2033
13. Holekamp N.M., Thomas M.A., and Pearson A. The safety profile of long-term, high-dose intraocular corticosteroid delivery. Am J Ophthalmol 139 (2005) 421-428